R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms POLAR BEAR
Most Recent Events
- 09 Feb 2024 Planned number of patients changed from 200 to 300.
- 09 Feb 2024 Planned End Date changed from 28 Feb 2026 to 28 Dec 2028.
- 09 Feb 2024 Planned primary completion date changed from 28 Feb 2023 to 28 Dec 2025.